Brand Name: Corlanor
Generic Name: ivabradine
Medication Class: Hyperpolarization-activated cyclic nucleotide-gated channel blocker
FDA Approval Date: April 15, 2015
What is Corlanor and its mechanism of action?
Corlanor (ivabradine) is an oral medication used for treating heart failure. It belongs to a new class of heart medications called hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blockers. It works by blocking hyperpolarization-activated cyclic nucleotide-gated (HCN) channel. HCN channels are also known as pacemaker channels because they generate and regulate the heart’s firing rate which controls heart rate. Corlanor reduces spontaneous pacemaker activity of the HCN channel and slows heart rate by inhibiting a specific current called funny current (If) generated from the HCN channel. It does so without affecting the heart’s ability to contract. It is beneficial to reduce heart rate in patients with heart failure because a fast heart rate is associated with increased mortality in heart failure patients. The heart does not work as hard when the heart rate is reduced. Corlanor reduces the risk of hospitalization in heart failure patients.
What is Corlanor used for treating?
Corlanor reduces the risk of hospitalization for worsening heart failure in patients with chronic heart failure. It is prescribed for patients with all of the following:
Heart failure is a chronic heart condition where the heart is unable to pump enough blood through the body’s circulation to supply the blood and oxygen needed by the body. In 2013, there were 5.1 million people with heart failure in the United States. Heart failure contributed to one in nine deaths in 2009. Half of the people diagnosed with heart failure die within 5 years. In 2010, there were 1 million hospitalizations due to heart failures. Twenty-nine percent of those who were admitted for heart failure were 65 or older.
Next: Efficacy, Side Effects, Dosing, Interactions